search
Back to results

Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal (PC-II)

Primary Purpose

Obesity, Phentermine Withdrawal

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Abrupt cessation of phentermine pharmacotherapy
Sponsored by
Center for Weight Management, California
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity treatment, Phentermine, Withholding treatment, Phentermine dependence

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Aged 18 years or older.
  2. Duration of phentermine treatment

    1. For LPT patients, on phentermine pharmacotherapy consecutively for 2 years or more and willing to take a drug holiday for 48 to 72 hours.
    2. LPT Patients who have taken drug holidays on their own during the most recent 2 years may be included provided there has not been a holiday in the 90 days prior to matriculation in this study.
    3. For APT patients, on phentermine pharmacotherapy for 7 to 14 days at 37.5 mg/day or less.

Exclusion Criteria:

  1. Patients with confirmed Axis I psychiatric conditions including depression, ADHD, SAD, bipolar disorder, substance abuse disorders (except caffeine and nicotine) and patients taking drugs for any of these conditions, including anti-depressant drugs, drugs for ADHD and lithium.
  2. Patients who were taking phentermine in combination with any other anti-obesity drug.
  3. Patients who are taking medications such as beta-blockers, which may modulate the stimulant effect of phentermine.
  4. Pregnant patients, nursing mothers, patients with uncontrolled hypertension, hyperthyroidism, severe cardiovascular disease, glaucoma, and known hypersensitivity to phentermine -

Sites / Locations

  • Center for Weight Management
  • Center for Weight Management

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

LPT

APT

Arm Description

Subjects treated with phentermine for 2 years or more.

Patients treated with phentermine for 7 to 14 days.

Outcomes

Primary Outcome Measures

Signs or symptoms of phentermine dependence (addiction)
Psychometric scales will be used for assessment of signs or symptoms of phentermine dependence, phentermine withdrawal, or phentermine cravings
Signs or symptoms of phentermine dependence (addiction)
Psychometric scales will be used for assessment of signs or symptoms of phentermine dependence, or phentermine cravings.

Secondary Outcome Measures

Full Information

First Posted
July 23, 2011
Last Updated
January 25, 2013
Sponsor
Center for Weight Management, California
Collaborators
American Society of Bariatric Physicians
search

1. Study Identification

Unique Protocol Identification Number
NCT01402674
Brief Title
Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal
Acronym
PC-II
Official Title
Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal
Study Type
Interventional

2. Study Status

Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
November 2012 (Actual)
Study Completion Date
November 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Center for Weight Management, California
Collaborators
American Society of Bariatric Physicians

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Phentermine, an amphetamine congener, is the most widely used anti-obesity drug in the U.S. Although phentermine is the agent-of-choice among physicians specializing in obesity treatment, the use of this drug for obesity treatment by other physicians has long been curtailed because misapprehensions regarding phentermine safety. Concerns of phentermine-induced adverse cardiovascular reactions and of phentermine-induced addiction are two fears that have had a profound negative impact on phentermine prescribing. Although warnings of high incidence rates of adverse cardiovascular and psychiatric effects are included in FDA labeling and are often repeated in published reviews, the few clinical reports in the peer-reviewed medical literature of such adverse effects are anecdotal. Fear of phentermine adverse effects does not inhibit the use of phentermine by obesity treatment specialists. A 2008 survey of prescribing practices found that 98% of bariatric medicine specialists used pharmacotherapy in treating obesity and that 97% of those prescribed phentermine as their first choice. The fear that phentermine has addiction potential appears to be a factor influencing curtailment of use. At the time that phentermine was approved in 1959 the expectations were that it would prove to be addicting, although perhaps less so than amphetamine. These expectations were based on the chemical structural similarities between phentermine and amphetamine and on evidence in rats that phentermine stimulated spontaneous activity. No evidence suggesting the drug had human addiction potential appeared in clinical trials conducted prior to approval. After 52 years of use there is no evidence in the peer-reviewed medical literature to support the hypothesis that phentermine has significant human addiction potential. Research in addiction medicine has undergone significant development in the last 50 years. Concepts of addiction have shifted from an early focus on tolerance and withdrawal to a current emphasis on the psychological components of dependence. Drug addiction has been redefined as drug dependence and standardized diagnostic criteria have been adopted for drug abuse, dependence and withdrawal. Psychometric testing methods have been developed, validated, and applied clinically for measurements of dependence, drug craving, and withdrawal for a wide variety of substances of abuse including cocaine, heroin, and amphetamine. Until recently, none of these addiction medicine metrics had been used to study the addiction potential of phentermine. Presumably, since phentermine is an amphetamine congener, any clinical characteristics of dependence or withdrawal should mimic those of amphetamine dependence or withdrawal. One recent retrospective study investigated symptoms occurring when patients treated with long-term phentermine in a weight management program abruptly ceased taking phentermine. The study found that patients on long-term phentermine who ceased phentermine abruptly by their choice did not have an amphetamine-like withdrawal symptom complex. Significantly there was no evidence of phentermine cravings. Further investigation is warranted. The addiction potential of a drug may be investigated by measuring the drug's propensity to induce dependence, to induce cravings for the drug, and for cessation of the drug to induce characteristic withdrawal symptoms. In the case of amphetamine withdrawal symptoms appear very quickly reaching a maximum at 48 hours after drug cessation. In this prospective study the addiction potential of phentermine will be assessed with validated psychometric scales to examine patients who have taken phentermine long-term for two years or more. Patients who have taken phentermine for 7 to 14 days will also be assessed. Participating patients who have taken phentermine long-term in this study will be asked to interrupt phentermine therapy for 48 hours to participate in the study. Scale examinations will be conducted at 24 and at 48 hours after drug cessation. Hypotheses Long-term phentermine-treated (LPT) patients do not develop phentermine dependence or cravings. LPT patients who cease taking phentermine abruptly do not experience amphetamine-like withdrawal symptoms. Specific Aims To compare the severity of phentermine dependence and craving between LPT patients and acute phentermine-treated (APT) patients To compare the severity of stimulant withdrawal symptoms before and after phentermine cessation in LPT patients. To examine the prevalence of phentermine dependence in LPT patients

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Phentermine Withdrawal
Keywords
Obesity treatment, Phentermine, Withholding treatment, Phentermine dependence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
269 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LPT
Arm Type
Active Comparator
Arm Description
Subjects treated with phentermine for 2 years or more.
Arm Title
APT
Arm Type
No Intervention
Arm Description
Patients treated with phentermine for 7 to 14 days.
Intervention Type
Drug
Intervention Name(s)
Abrupt cessation of phentermine pharmacotherapy
Other Intervention Name(s)
Phentermine-HCL, generic
Intervention Description
Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
Primary Outcome Measure Information:
Title
Signs or symptoms of phentermine dependence (addiction)
Description
Psychometric scales will be used for assessment of signs or symptoms of phentermine dependence, phentermine withdrawal, or phentermine cravings
Time Frame
Long-term cohort subjects on phentermine 2 years or more.
Title
Signs or symptoms of phentermine dependence (addiction)
Description
Psychometric scales will be used for assessment of signs or symptoms of phentermine dependence, or phentermine cravings.
Time Frame
Short-term cohort subjects on phentermine (APT) for 7 to 14 days.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18 years or older. Duration of phentermine treatment For LPT patients, on phentermine pharmacotherapy consecutively for 2 years or more and willing to take a drug holiday for 48 to 72 hours. LPT Patients who have taken drug holidays on their own during the most recent 2 years may be included provided there has not been a holiday in the 90 days prior to matriculation in this study. For APT patients, on phentermine pharmacotherapy for 7 to 14 days at 37.5 mg/day or less. Exclusion Criteria: Patients with confirmed Axis I psychiatric conditions including depression, ADHD, SAD, bipolar disorder, substance abuse disorders (except caffeine and nicotine) and patients taking drugs for any of these conditions, including anti-depressant drugs, drugs for ADHD and lithium. Patients who were taking phentermine in combination with any other anti-obesity drug. Patients who are taking medications such as beta-blockers, which may modulate the stimulant effect of phentermine. Pregnant patients, nursing mothers, patients with uncontrolled hypertension, hyperthyroidism, severe cardiovascular disease, glaucoma, and known hypersensitivity to phentermine -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ed J Hendricks, MD
Organizational Affiliation
Center for Weight Management
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Weight Management
City
Roseville
State/Province
California
ZIP/Postal Code
95661
Country
United States
Facility Name
Center for Weight Management
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
20592662
Citation
Hendricks EJ, Greenway FL. A study of abrupt phentermine cessation in patients in a weight management program. Am J Ther. 2011 Jul;18(4):292-9. doi: 10.1097/MJT.0b013e3181d070d7.
Results Reference
background
PubMed Identifier
21527891
Citation
Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011 Dec;19(12):2351-60. doi: 10.1038/oby.2011.94. Epub 2011 Apr 28.
Results Reference
background
PubMed Identifier
19300434
Citation
Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring). 2009 Sep;17(9):1730-5. doi: 10.1038/oby.2009.69. Epub 2009 Mar 19.
Results Reference
background
PubMed Identifier
9698974
Citation
Kampman KM, Volpicelli JR, McGinnis DE, Alterman AI, Weinrieb RM, D'Angelo L, Epperson LE. Reliability and validity of the Cocaine Selective Severity Assessment. Addict Behav. 1998 Jul-Aug;23(4):449-61. doi: 10.1016/s0306-4603(98)00011-2.
Results Reference
background
PubMed Identifier
16128721
Citation
McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005 Sep;100(9):1320-9. doi: 10.1111/j.1360-0443.2005.01160.x.
Results Reference
background
PubMed Identifier
17629443
Citation
McGregor C, Srisurapanont M, Mitchell A, Longo MC, Cahill S, White JM. Psychometric evaluation of the Amphetamine Cessation Symptom Assessment. J Subst Abuse Treat. 2008 Jun;34(4):443-9. doi: 10.1016/j.jsat.2007.05.007. Epub 2007 Jul 13.
Results Reference
background
PubMed Identifier
10197890
Citation
Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust N Z J Psychiatry. 1999 Feb;33(1):89-93. doi: 10.1046/j.1440-1614.1999.00517.x.
Results Reference
background
PubMed Identifier
8174499
Citation
Tiffany ST, Singleton E, Haertzen CA, Henningfield JE. The development of a cocaine craving questionnaire. Drug Alcohol Depend. 1993 Dec;34(1):19-28. doi: 10.1016/0376-8716(93)90042-o.
Results Reference
background

Learn more about this trial

Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal

We'll reach out to this number within 24 hrs